Welcome to the WCN 2023 Interactive Program

Session Description:

Myasthenia gravis is a chronic, autoimmune disorder that affects the function of the neuromuscular junction, leading to fluctuating, unpredictable symptoms that impact daily life. Treatment of myasthenia gravis has traditionally focused on symptomatic management; however, many of these symptomatic treatments are associated with toxicity and have a delayed onset of effect. The development of targeted therapies that address the underlying pathophysiology of the disorder has the potential to transform management and improve long-term outcomes. In this session, we will provide an overview of myasthenia gravis pathophysiology and the associated burden of current treatments; evaluate developments in the treatment of myasthenia gravis; and describe the impact that these new, targeted therapies have on patient outcomes.